Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Lyons, Renee
and
Rudd, Anthony G.
2007.
Health Policy and Outcomes 2006.
Stroke,
Vol. 38,
Issue. 2,
p.
229.
van den Bos, Trudi
Visser-Meily, Anne
and
van Exel, Job
2007.
Optimalisering van de zorg aan CVA-patiënten in de huisartsenpraktijk.
Huisarts en Wetenschap,
Vol. 50,
Issue. 11,
p.
792.
Hoogendoorn, Martine
Welsing, Paco
and
Rutten-van Mölken, Maureen P.M.H.
2008.
Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
Current Medical Research and Opinion,
Vol. 24,
Issue. 1,
p.
51.
van den Bos, Trudi
Visser-Meily, Anne
and
van Exel, Job
2008.
De praktijkondersteuner meer betrokken bij de zorg aan CVA-patiënten.
Tijdschrift voor praktijkondersteuning,
Vol. 3,
Issue. 1,
p.
7.
Grimes, Tamasine
Duggan, Catherine
Gallagher, Paul
and
Strawbridge, Judith
2009.
Care of the stroke patient—communication between the community pharmacist and prescribers in the Republic of Ireland.
Pharmacy World & Science,
Vol. 31,
Issue. 6,
p.
648.
Luengo-Fernandez, Ramon
Gray, Alastair M.
and
Rothwell, Peter M.
2009.
Costs of Stroke Using Patient-Level Data.
Stroke,
Vol. 40,
Issue. 2,
Sivenius, J.
Torppa, J.
Tuomilehto, J.
Immonen-Räihä, P.
Kaarisalo, M.
Sarti, C.
Kuulasmaa, K.
Mähönen, M.
Lehtonen, A.
and
Salomaa, V.
2009.
Modelling the Burden of Stroke in Finland until 2030.
International Journal of Stroke,
Vol. 4,
Issue. 5,
p.
340.
Baeten, Stefan A
van Exel, N Job A
Dirks, Maaike
Koopmanschap, Marc A
Dippel, Diederik WJ
and
Niessen, Louis W
2010.
Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach.
Cost Effectiveness and Resource Allocation,
Vol. 8,
Issue. 1,
Vemer, Pepijn
and
Rutten-van Mölken, Maureen P.M.H.
2010.
Crossing Borders: Factors Affecting Differences in Cost-Effectiveness of Smoking Cessation Interventions between European Countries.
Value in Health,
Vol. 13,
Issue. 2,
p.
230.
Gustavsson, Anders
Svensson, Mikael
Jacobi, Frank
Allgulander, Christer
Alonso, Jordi
Beghi, Ettore
Dodel, Richard
Ekman, Mattias
Faravelli, Carlo
Fratiglioni, Laura
Gannon, Brenda
Jones, David Hilton
Jennum, Poul
Jordanova, Albena
Jönsson, Linus
Karampampa, Korinna
Knapp, Martin
Kobelt, Gisela
Kurth, Tobias
Lieb, Roselind
Linde, Mattias
Ljungcrantz, Christina
Maercker, Andreas
Melin, Beatrice
Moscarelli, Massimo
Musayev, Amir
Norwood, Fiona
Preisig, Martin
Pugliatti, Maura
Rehm, Juergen
Salvador-Carulla, Luis
Schlehofer, Brigitte
Simon, Roland
Steinhausen, Hans-Christoph
Stovner, Lars Jacob
Vallat, Jean-Michel
den Bergh, Peter Van
van Os, Jim
Vos, Pieter
Xu, Weili
Wittchen, Hans-Ulrich
Jönsson, Bengt
and
Olesen, Jes
2011.
Cost of disorders of the brain in Europe 2010.
European Neuropsychopharmacology,
Vol. 21,
Issue. 10,
p.
718.
Asmus-Szepesi, Kirsten JE
de Vreede, Paul L
Nieboer, Anna P
van Wijngaarden, Jeroen DH
Bakker, Ton JEM
Steyerberg, Ewout W
and
Mackenbach, Johan P
2011.
Evaluation design of a reactivation care program to prevent functional loss in hospitalised elderly: A cohort study including a randomised controlled trial.
BMC Geriatrics,
Vol. 11,
Issue. 1,
Verhoef, Talitha I
Redekop, William K
van Schie, Rianne MF
Bayat, Samira
Daly, Ann K
Geitona, Mary
Haschke-Becher, Elisabeth
Hughes, Dyfrig A
Kamali, Farhad
Levin, Lars-Åke
Manolopoulos, Vangelis G
Pirmohamed, Munir
Siebert, Uwe
Stingl, Julia C
Wadelius, Mia
de Boer, Anthonius
and
Maitland-van der Zee, Anke-Hilse
2012.
Cost–Effectiveness of Pharmacogenetics in Anticoagulation: International Differences in Healthcare Systems and Costs.
Pharmacogenomics,
Vol. 13,
Issue. 12,
p.
1405.
van Eeden, Mitchel
van Heugten, Caroline M
and
Evers, Silvia MAA
2012.
The economic impact of stroke in The Netherlands: the €-restore4stroke study.
BMC Public Health,
Vol. 12,
Issue. 1,
Polese, Janaíne Cunha
Pinheiro, Marina de Barros
Basilio, Marluce Lopes
Parreira, Verônica F.
Britto, Raquel Rodrigues
and
Teixeira-Salmela, Luci Fuscaldi
2013.
Estudo de seguimento da função motora de indivíduos pós-acidente vascular encefálico.
Fisioterapia e Pesquisa,
Vol. 20,
Issue. 3,
p.
222.
Tummers, Johanneke FMM
Schrijvers, Augustinus JP
and
Visser-Meily, Johanna MA
2013.
A qualitative study of stakeholder views on the effects of provider payment on cooperation, quality of care and cost-containment in integrated stroke care.
BMC Health Services Research,
Vol. 13,
Issue. 1,
Verhoef, Talitha I
Redekop, William K
Veenstra, David L
Thariani, Rahber
Beltman, Peter A
van Schie, Rianne MF
de Boer, Anthonius
and
Maitland-van der Zee, Anke-Hilse
2013.
Cost–Effectiveness of Pharmacogenetic-Guided Dosing of Phenprocoumon in Atrial Fibrillation.
Pharmacogenomics,
Vol. 14,
Issue. 8,
p.
869.
Verhoef, Talitha I.
Redekop, William K.
Hasrat, Fazila
de Boer, Anthonius
and
Maitland-van der Zee, Anke Hilse
2014.
Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings.
American Journal of Cardiovascular Drugs,
Vol. 14,
Issue. 6,
p.
451.
Ewara, Emmanuel M.
Isaranuwatchai, Wanrudee
Bravata, Dawn M.
Williams, Linda S.
Fang, Jiming
Hoch, Jeffrey S.
and
Saposnik, Gustavo
2015.
The Iscore Predicts Total Healthcare Costs Early after Hospitalization for an Acute Ischemic Stroke.
International Journal of Stroke,
Vol. 10,
Issue. 8,
p.
1179.
van Vliet, Paulette
Pomeroy, Valerie M.
Wolf, Steven L.
and
Kwakkel, Gert
2015.
Time to Empower People With Stroke.
Journal of Neurologic Physical Therapy,
Vol. 39,
Issue. 3,
p.
139.
Verhoef, Talitha I
Redekop, William K
de Boer, Anthonius
and
Maitland-van der Zee, Anke Hilse
2015.
Economic Evaluation of a Pharmacogenetic Dosing Algorithm for Coumarin Anticoagulants in the Netherlands.
Pharmacogenomics,
Vol. 16,
Issue. 2,
p.
101.